Aerocrine has partnered with Microsoft in a pilot project to send data from nitric oxide monitoring devices to the cloud for analysis.
U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.
Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.
Apple's HealthKit data-sharing platform for mobile health apps has been pulled from the iPhone 6's operating system after an upgrade to iOS 8 disrupted cellular service, resulting in a bucketful of delayed app launches or upgrades, to the benefit of competitors.
GlaxoSmithKline and San Diego-based Avalon Ventures have crafted two new biotechs which will explore the therapeutic potential of a pair of new drugs. These companies, dubbed Silarus Therapeutics and Thyritope Biosciences, will each get a $10 million Series A and research support from the venture group and its Big Pharma partner, which will consider whether it wants to snap up the companies once they hit the proof-of-concept stage a few years down the pipeline.
Japan's Global Health Initiative Technology Fund is investing $15.3 million to speed the development of new drugs and vaccines for malaria, dengue and Chagas disease.
MiMedx Group announced a second partnership with a major medical device firm to sell its regenerative biomaterials product. This time, it is with orthopedic player Zimmer. Last year, MiMedx disclosed a similar deal with Medtronic.
With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.